288-42-6Relevant academic research and scientific papers
Gold(I)-catalyzed protodecarboxylation of (Hetero)aromatic carboxylic acids
Dupuy, Stéphanie,Nolan, Steven P.
supporting information, p. 14034 - 14038 (2013/11/19)
Readily available, inexpensive and easy to handle, carboxylic acids have been shown to be very effective, greener coupling partners compared to costly organometallic reagents for the formation of C-C bonds. The use of well-defined gold complexes furnished 3 in slightly better yield with butyric acid, and in quantitative yield with adamantane-1-carboxylic acid. All reactions reached completion within 16 h. As with silver systems, this reactivity trend highlights, as previously observed, the benefits of potential coordinating groups in the ortho position to the gold binding site, which possibly facilitate the decarboxylation step. Additional reaction time and increased temperatures were necessary to afford the gold aryl products in satisfactory yields. Yet, some substrates such as 2-nitrobenzoic acids reacted poorly and could only be transformed in 50% yield.
Lipopeptide Compounds and Their Use
-
, (2011/10/04)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.
Reactivity of neutral nitrogen donors in square-planar d8 metal complexes: The system chloro(2,2′:6′,2″-terpyridine)platinum(II) cation with five-membered N-donor heterocycles in methanol
Pitteri, Bruno,Bortoluzzi, Marco
, p. 2698 - 2704 (2008/10/09)
The kinetics of the forward and reverse steps of the reaction [Pt(terpy)Cl]+ + nu ? [Pt(terpy)(nu)]2+ + Cl- (terpy = 2,2′:6′,2″-terpyridine, nu = one of a number of thiazoles, oxazole, isoxazole, imidazole, pyrazole and 3,5-dimethylpyrazole, covering a wide range of basicities) have been studied in methanol at 25 °C. Both forward and reverse reactions obey the usual two-term rate law observed in square-planar substitution. The second-order rate constants for the forward reactions, k2f, show a slight dependence upon the basicity of the entering nu, while the steric hindrance due to the presence of one methyl group in the α position to the nitrogen markedly decreases the reactivity. The second-order rate constants for the reverse reactions, k2r, are very sensitive to the nature of the leaving group and a plot of log k2r against the pKa of the conjugate acids of the unhindered five-membered N-donors is linear with a slope of -0.51. The results are compared with data from the literature regarding a series of pyridines reacting with the [Pt(terpy)Cl]+ cation under the same experimental conditions. Both in the forward and in the reverse reaction, the reactivity depends not only upon the ligand basicity but also upon the nature of the nucleophile in the order: (thiazoles, oxazole, isoxazole, imidazole, pyrazoles) > pyridines for the entry of N-donors and on the contrary for the displacement by Cl-. Steric retardation, due to the presence of a methyl group in the α position to the nitrogen, is remarkably lower for five-membered N-donors if compared to pyridines both in the forward and in the reverse reaction.
PROCESS FOR THE RECOVERY OF OXAZOLE
-
Page 17-18, (2008/06/13)
A process for the recovery of oxazole comprising contacting a mixture comprising oxazole and acetonitrile with an acid to form an acid salt of oxazole; separating acid salt of the oxazole from the mixture; and neutralizing the acid salt of oxazole separated from the mixture to release oxazole.
Gastrin and cholecystokinin receptor ligands(II)
-
, (2008/06/13)
Substituted imidazoles (1) are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure. Pharmaceutical compositions containing the novel imidazoles and pharmaceutical methods using them, alone and in conjunction with other drugs, especially diuretics and non-steroidal antiinflammatory drugs (NSAID's) are also described.
Cocaine receptor binding ligands
-
, (2008/06/13)
The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases.
Viral polymerase inhibitors
-
, (2008/06/13)
An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; ---- represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
-
, (2008/06/13)
Piperazine carboxamide intermediates of HIV protease inhibitors and a process for their preparation are disclosed. The piperazine carboxamide compounds are of Formula (III): wherein R1, R2, R3, R4, R5, and R6 are defined herein. The process for preparing the intermediates comprises coupling an iminium salt of Formula I: with a metallated derivative of a compound of Formula (II): R1—H??(II), wherein L? is a counterion. A process for preparing the iminium salt of Formula (I) is also disclosed, as is a process for preparing HIV protease inhibitors from Compound III.
Antidiabetic agents
-
, (2008/06/13)
The present invention provides compounds of Formula (I): wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
Macrocyclic peptides active against the hepatitis C virus
-
, (2008/06/13)
The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. wherein W, R21, R22, R3, R4, D and A are as defined herein, or a pharmaceutically acceptable salts or ester thereof.
